{
    "ticker": "PLX",
    "name": "Protalix BioTherapeutics, Inc.",
    "description": "Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of rare diseases. Founded in 2003, Protalix utilizes its proprietary ProCellEx\u00ae protein expression system to produce therapeutic proteins in plant cells, offering advantages such as reduced manufacturing costs and enhanced safety profiles. The company\u2019s lead product, Elelyso\u00ae (taliglucerase alfa), is an enzyme replacement therapy approved for the treatment of Gaucher disease. Protalix is also advancing a pipeline of product candidates targeting a range of unmet medical needs, including treatments for Fabry disease and other lysosomal storage disorders. With a commitment to scientific excellence and patient-centric solutions, Protalix aims to bring forth transformative therapies that improve the quality of life for patients. The company collaborates with various healthcare organizations and stakeholders to enhance its research and development efforts, striving to address the challenges faced by patients with rare genetic disorders. Protalix\u2019s innovative approach and dedication to rare disease treatment position it as a key player in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Carmiel, Israel",
    "founded": "2003",
    "website": "http://www.protalix.com",
    "ceo": "Dr. David Aviezer",
    "social_media": {
        "twitter": "https://twitter.com/Protalix",
        "linkedin": "https://www.linkedin.com/company/protalix-biotherapeutics/"
    },
    "investor_relations": "http://www.protalix.com/investors",
    "key_executives": [
        {
            "name": "Dr. David Aviezer",
            "position": "CEO"
        },
        {
            "name": "Eran Gozlan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Products",
            "products": [
                "Elelyso\u00ae"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "PRX-102 for Fabry Disease",
                "PRX-110 for other lysosomal storage disorders"
            ]
        }
    ],
    "seo": {
        "meta_title": "Protalix BioTherapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Protalix BioTherapeutics, Inc., a biopharmaceutical company specializing in innovative therapies for rare diseases. Learn about their products and research efforts.",
        "keywords": [
            "Protalix",
            "Biotechnology",
            "Rare Diseases",
            "Elelyso",
            "Gaucher Disease",
            "Fabry Disease"
        ]
    },
    "faq": [
        {
            "question": "What is Protalix BioTherapeutics known for?",
            "answer": "Protalix BioTherapeutics is known for developing innovative therapies for rare diseases, including its enzyme replacement therapy for Gaucher disease."
        },
        {
            "question": "Who is the CEO of Protalix?",
            "answer": "Dr. David Aviezer is the CEO of Protalix BioTherapeutics, Inc."
        },
        {
            "question": "Where is Protalix headquartered?",
            "answer": "Protalix is headquartered in Carmiel, Israel."
        },
        {
            "question": "What are Protalix's main products?",
            "answer": "Protalix's main product is Elelyso\u00ae, with additional pipeline candidates targeting various rare diseases."
        },
        {
            "question": "When was Protalix founded?",
            "answer": "Protalix was founded in 2003."
        }
    ],
    "competitors": [
        "ALNY",
        "BMRN",
        "AVEO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}